MBRX•Moleculin Biotech held its annual shareholder meeting on Oct. 9, 2026. Shareholders approved a stock plan increase of 3,861,894 shares to 3,875,999 and a potential reverse stock split at a ratio of 1-for-2 to 1-for-20; a proposal to remove supermajority amendment thresholds failed.
Shareholders ratified Grant Thornton as the independent registered public accounting firm for the year ending Dec. 31, 2026, and gave advisory approval to executive compensation. They also adopted an amendment increasing shares authorized under the 2024 stock plan by 3,861,894 to 3,875,999.
A proposed charter change to remove supermajority amendment thresholds failed. Shareholders separately authorized a potential reverse stock split, with a ratio ranging from 1-for-2 to 1-for-20.
